Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Debunking Myths in the US Healthcare System
Your Article Summary
Long-Term Effects of Pamidronate in Thalassemic Patients with Severe Bone Mineral Density Deficits
Hemoglobin, 10/23/09
Leung TF et al. – Osteoporosis is a common complication in thalassemia major (TM). Our previous study demonstrated severe bone mineral density (BMD) deficits at spine and hip in 62 and 35% of TM patients. This study assessed the effects of different treatments (calcium, vitamin D and bisphosphonate) on patients' BMD, which was measured at baseline and after 3–year treatments by dual energy X–ray absorptiometry (DEXA). Long–term improvement in BMD in TM patients was observed with bisphosphonate but not calcium and vitamin D treatment.
Related Articles
Longitudinal Cohort Study of Risk Factors in Cancer Patients of Bisphosphonate-Related Osteonecrosis of the Jaw
Journal of Clinical Oncology, 10/12/09
Relevance Score: 77%
Today in Bone Metabolism...keeping you current
Receive free subspecialty "5-minute updates" via email
Inhibition of osteoclast differentiation and bone resorption by rotenone, through down-regulation of RANKL-induced c-Fos and NFATc1 expression
Bone , 12/11/09
Ubiquitous overexpression of Hey1 transcription factor leads to osteopenia and chondrocyte hypertrophy in bone
Bone , 12/11/09
Gene expression profile in osteoclasts from patients with Pagets disease of bone
Bone , 12/11/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


